This page shows the SEC filing summaries for Bionano Genomics, Inc..
Bionano Genomics, Inc.
CIK: 1411690 · 3 filings tracked
Filing History
1
8-K
Material Event
May 6, 2026
- Appointment of long-term Board member Dr. Albert A. Luderer as Interim CEO to ensure stability.
- Leadership transition signals a potential strategic reset for the company's genome mapping business.
- Focus on institutional continuity during a critical period of financial pressure.
2
10-K
Annual Report
March 23, 2026
- OGM secured a new Category I CPT code for constitutional genetic disorders and a 47% payment increase for existing blood cancer codes, effective January 2026.
- The company sees a substantial $10.0 billion yearly market opportunity for its Optical Genome Mapping (OGM) technology.
- Strong scientific validation continues with 450 peer-reviewed OGM publications in 2025, contributing to over 1,800 total publications.
3
8-K
Material Event
March 23, 2026
- Aggressive 55% annual cost reduction significantly improved gross profit margin to 46%.
- 47% payment rate increase for OGM in hematologic malignancies boosts future revenue potential.
- Positive 2026 sales forecast ($30M-$33M) indicates expected growth.
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.